Press Room

MDOUTLOOK®, the oncology intelligence initiative powered by The Arcas Group, today announced results from its 3rd Annual Quick Poll research launched following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Within one week, 281 cancer treaters from 22 countries responded, making it the first market feedback available post-ASCO.

A new probe by the British scientists into the commonest form of kidney cancer have unveiled a batch of new gene mutations linked to it, suggesting even this apparently "straightforward" cancer type can be divided into subtypes requiring tailored treatment.

The company is providing a preliminary update on Trial 103 (the first stage of the Phase II program) in which MGCD265 is administered in combination with either erlotinib (Tarceva®) or docetaxel (Taxotere®) in solid tumor patients.

Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types.

Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality. Characterization of microRNA (miRNA) expression of RCC will help disclose new pathogenic pathways in tumourigenesis and progression and may lead to the development of molecular biomarkers and target-specific therapies for diagnosis, prognostication and treatment.

The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting. As a result, Votrient/Patorma will become the market leader and will garner sales of nearly $630 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.